Bioniz was founded on an idea that small peptides could be rationally designed to selectively inhibit functionally redundant cytokines by targeting receptors that are shared within a family of cytokines. Many diseases are driven by the collective dysregulation of multiple cytokines and are, therefore, inherently beyond the reach of current therapies, which lack either the breadth or the specificity to address this more complex pathology.
Our M3 Technology platform dissects the evolutionary biological concept of “redundancy” that exists within families of cytokines, which is defined as several cytokines sharing a common receptor and therefore exhibiting redundant functionality. It has become increasingly understood that members of a cytokine family possess overlapping responsibilities to ensure the vital maintenance of an immune response in the event the primary family member is either disrupted or dysregulated.
